{"filings":[{"id":2253676,"accession_number":"0001140361-26-032946","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2026-08-14T11:55:46+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin reports Q2 net loss $9.2M; FDA agrees on Phase 3 design for belapectin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.2M ($0.14/share) vs $7.6M ($0.12/share) in Q2 2025; R&D $2.1M, G&A $1.8M.","FDA alignment on Phase 3 trial design for belapectin in MASH cirrhosis; protocol submission expected 3Q 2026.","Chairman Richard Uihlein converted $105.8M debt (principal $91M + interest $14.8M) into 34.4M shares, effective July 31, 2026.","Cash $13.2M at June 30, 2026; $10M line of credit available; cash runway through June 2027.","NAVIGATE trial data published in Hepatology and Gastro Hep Advances; EASL presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2033877,"accession_number":"0001140361-26-031058","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2026-08-04T11:50:16+00:00","items":["3.02"],"status":"ready","headline":"Galectin Therapeutics converts $105.8M debt to equity, eliminating all outstanding notes from Chairman Uihlein","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted $91.0M principal + $14.8M accrued interest ($105.8M total) into 34,376,167 shares at ~$3.07 blended price.","Post-conversion shares outstanding: 100,849,644; Uihlein owns ~44.3% voting power (49.3% including warrants).","Sixth $10M credit facility (Dec 2025) remains undrawn and available; no notes issued under it.","Company must register resale of shares within 180 days per registration rights provisions.","CEO says conversion 'transformative' for balance sheet, strengthens ability to advance belapectin program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1204476,"accession_number":"0001140361-26-026031","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2026-06-23T11:51:12+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin reaches FDA agreement on Phase 3 endpoint for belapectin in MASH cirrhosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on primary endpoint: composite liver outcome including prevention of large esophageal varices (>5 mm).","Company to submit Phase 3 protocol in Q3 2026; plans to evaluate single 2 mg dose of belapectin.","Galectin actively exploring strategic and financial partnerships to support development and commercialization.","FDA acknowledged substantial unmet medical need in MASH cirrhosis patients with portal hypertension.","Company expects Phase 3 trial size comparable to NAVIGATE trial (global Phase 2b/3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452636,"accession_number":"0001140361-26-021496","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2026-05-15T11:50:30+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Q1 net loss narrows to $5.1M; belapectin data at EASL, FDA meeting ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.1M ($0.08 per share) vs $9.6M ($0.15) in Q1 2025; R&D expense fell to $2.2M from $6.5M.","Cash $14.1M as of Mar 31, plus $10M credit line from chairman; company expects to fund ops through May 2027.","Belapectin 2 mg/kg showed statistically significant liver stiffness reductions (FibroScan) at Weeks 26, 52, 78 in NAVIGATE trial.","Oral/poster presentations at EASL Congress May 28-30; Type-C FDA meeting scheduled for Q2 2026.","Board appointed Dr. Henry Brem in Jan 2026; KOL event on MASH cirrhosis held in March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101602,"accession_number":"0001140361-26-012158","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics reports FY2025 net loss $31M; belapectin data for EASL upcoming","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.0M ($0.48/share) vs $47.2M ($0.76) in 2024; R&D expense down to $14.3M from $36.6M.","Cash $17.7M plus $10M credit line from chairman; runway through April 2027.","Belapectin NAVIGATE trial: varices incidence reduced 49.3% in per-protocol (p=0.04); U.S. subgroup 68.1% (p=0.02).","Additional biomarker data (FibroScan, ELF, PRO-C3) support antifibrotic activity; oral/poster presentations at EASL 2026.","Upcoming FDA meeting in Q2 2026 to align on next steps; no approved therapy for MASH cirrhosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101601,"accession_number":"0001140361-26-009735","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Galectin Therapeutics appoints Dr. Henry Brem to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Henry Brem appointed as independent director effective March 12, 2026.","Brem is a neurosurgeon-scientist at Johns Hopkins and former Director of Neurosurgery.","He brings expertise in translational medicine and clinical development of novel therapies.","Will receive standard non-employee director compensation per existing program.","No reportable transactions between Brem and the company under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101600,"accession_number":"0001140361-26-001866","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Galectin Therapeutics approves $450k in retention bonuses for CMO and CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approves $300,000 cash retention bonus for CMO Dr. Khurram Jamil.","Board approves $150,000 cash retention bonus for CFO Jack Callicutt.","Bonuses payable in three equal installments on June 1, Sep 1, Dec 1, 2026.","Bonuses require repayment if officers voluntarily resign without good reason or are terminated for cause before Dec 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101599,"accession_number":"0001140361-26-000994","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Marc Rubin resigns from Galectin Therapeutics board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marc Rubin resigned from the Board of Directors on January 10, 2026.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117948,"accession_number":"0001140361-25-046115","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Galectin Therapeutics receives FDA alignment on belapectin trial design; secures $10M credit line","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA written response on belapectin shows alignment on patient population for registration trial; follow-up Type C meeting planned.","Follow-up meeting to finalize trial design and present biomarker data from AASLD meeting not included in prior submission.","Entered $10M unsecured, convertible line of credit from chairman Richard E. Uihlein; maturity extended to June 30, 2027.","Existing credit facilities also extended; company expects funding through at least March 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117947,"accession_number":"0001140361-25-044711","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galectin Therapeutics shareholders elect all 11 directors, approve say-on-pay, set frequency at 3 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected with >25M votes for each; highest was Benjamin S. Carson Sr. at 25.9M.","Advisory say-on-pay resolution approved: 25.3M for, 639k against, 310k abstain.","Shareholders chose a 3-year frequency for future say-on-pay votes (22.1M votes for 3 years).","Ratification of Cherry Bekaert LLP as independent auditor for FY2025 passed with 45.5M for, 142k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117946,"accession_number":"0001140361-25-044148","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin reports NAVIGATE biomarker data consistent with clinical benefit; FDA package submitted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In patients with ELF >11.3 (high-risk), new varices occurred in 22.7% on belapectin vs 42.9% on placebo.","PRO-C3, a marker of fibrogenesis, showed >50% reduction from baseline with belapectin 2 mg/kg vs placebo at 18 months.","Belapectin reduced progression of liver stiffness on FibroScan (≥30% increase or ≥5 kPa rise) vs placebo.","No drug-related serious adverse events; discontinuation rates similar to placebo in NAVIGATE.","FDA package submitted; company exploring strategic partnerships and extended cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117945,"accession_number":"0001140361-25-042118","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin reports Q3 net loss of $0.13/sh; cash $11.5M; NAVIGATE data submitted to FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.2M ($0.13/share) vs $11.2M ($0.18/share) in Q3 2024; R&D spend down to $2.6M as NAVIGATE trial ended.","Cash and equivalents $11.5M at Sep 30; plus $10M line of credit from chairman; runway through June 2026.","New 18-month NAVIGATE biomarker data showed belapectin reduced portal hypertension risk categories vs placebo.","FDA data package submitted for belapectin in MASH cirrhosis; agency feedback expected by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117944,"accession_number":"0001140361-25-041275","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin Therapeutics presents NAVIGATE trial: belapectin reduces varices, biomarkers improve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Belapectin 2 mg/kg reduced new varices vs placebo across all ELF risk categories at 18 months; in highest risk (ELF>11.3): 22.7% vs 42.9%.","Pro-C3 biomarker showed >50% reduction from baseline at 18 months with belapectin 2 mg/kg vs placebo (mean -6.4 vs -4.5 ng/mL).","Higher proportion of belapectin 2 mg/kg patients achieved ≥20% reduction in YKL-40 (33.8% vs 23.1%); fewer had ≥20% PRO-C4 increase (3% vs 13%).","At 36 months, cumulative new varices incidence 12.4% (belapectin 2 mg/kg) vs 23.4% (placebo), sustained benefit.","Safety profile encouraging; adverse events and serious adverse events comparable to placebo, no drug-related SAEs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134407,"accession_number":"0001140361-25-034242","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin Therapeutics updates corporate presentation; no new specific data in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated September 2025 covers pipeline and strategy, but no clinical or financial figures are disclosed in the filing text.","Lead candidate belapectin (galectin-3 inhibitor) is highlighted without new trial results or milestones.","Forward-looking statements caution that actual results may differ materially from projections.","Investors should review the full presentation on the company's website for material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134406,"accession_number":"0001140361-25-031041","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Q2 net loss $7.6M ($0.12/sh); secures $10M credit line from chairman","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss applicable to common stockholders of $7.6M ($0.12 per share) vs $12.4M ($0.20) in Q2 2024.","R&D expenses fell to $3.3M from $9.8M due to NAVIGATE trial completion in Q1 2025.","Cash and equivalents $13.8M at June 30; $10M line of credit from chairman closed July 8.","Company expects sufficient funding to operate through June 30, 2026.","NAVIGATE data at EASL showed belapectin reduced liver stiffness progression over 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134405,"accession_number":"0001140361-25-025295","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Galectin Therapeutics secures $10M line of credit from Chairman Uihlein; extends existing debt to Sept 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Richard E. Uihlein provides up to $10M unsecured line of credit; draws through April 2026, principal & interest due Sept 30, 2026.","Interest at Applicable Federal Rate (currently 4.05%) plus 2%; conversion price floor $3.00 per share.","Up to 200,000 warrants issued ratably; exercise price 150% of closing price, capped at $10, floor $3.","Company extends existing $81M in convertible notes & lines of credit to September 30, 2026.","Board approves $100K retention bonuses for CMO Dr. Khurram Jamil & CFO Jack Callicutt; partnership bonus if belapectin deal by Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151224,"accession_number":"0001140361-25-022574","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NAVIGATE trial: belapectin 2mg significantly reduces new varices in MASH cirrhosis patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In per-protocol, belapectin 2mg reduced new varices incidence at 18 months (p=0.04) vs placebo.","Liver stiffness measure improved -12.3% mean change for belapectin 2mg vs -3.1% for placebo.","Fewer subjects on belapectin showed worsening LSM >30% or >10 kPa (p=0.03 for 2mg, p=0.02 for 4mg).","Safety profile comparable to placebo: no drug-related SAEs, no DILI, similar discontinuation rates.","U.S. subgroup showed significant varices reduction with belapectin 2mg (p=0.02)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151223,"accession_number":"0001140361-25-019151","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics Q1 net loss $9.6M; Belapectin shows liver stiffness reduction at EASL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q1 2025 was $9.6M ($0.15 per share) vs $11.5M ($0.19) in Q1 2024.","Cash and equivalents $7.4M as of March 31, 2025; additional $11M available under lines of credit; runway through August 2025.","Belapectin 2 mg/kg showed statistically significant reduction in liver stiffness from baseline at weeks 26, 52, 78 (p<0.02).","Proportion of patients with >30% worsening in liver stiffness: 11.7% for belapectin vs 23.9% for placebo (51% fewer, p=0.03).","Data presented at EASL May 2025; Fast Track Designation for belapectin in MASH cirrhosis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151222,"accession_number":"0001140361-25-018277","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Belapectin shows 49.3% reduction in new varices in MASH cirrhosis patients at EASL 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Belapectin 2 mg/kg reduced new varices by 49.3% vs placebo (p=0.04) in per-protocol population (n=287).","Only 4.3% of 2 mg/kg group had >10 kPa liver stiffness increase vs 12.5% placebo (p=0.02).","Safety profile comparable to placebo; no drug-related serious adverse events reported.","NAVIGATE trial: 355 patients randomized 1:1:1 to belapectin 2/4 mg/kg or placebo every other week for 18 months.","Data presented as late-breaking oral at EASL 2025 Congress on May 10, 2025 in Amsterdam."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170110,"accession_number":"0001140361-25-011174","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics reports FY2024 net loss of $47.2M; NAVIGATE varices reduction in per-protocol","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $47.2M ($0.76/sh) vs $44.5M ($0.74/sh) in 2023; R&D spend $36.6M up from $32.1M.","Cash $15.1M at Dec 31, 2024; new $5M line of credit from chairman in March 2025; cash runway through Aug 2025.","NAVIGATE trial: varices incidence reduced 49.3% (p=0.04) in per-protocol for belapectin 2 mg vs placebo.","In US per-protocol patients, varices reduced 68.1% (p=0.02); ITT population did not reach significance.","Additional biomarker data expected Q2 2025; belapectin has FDA Fast Track Designation for MASH cirrhosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170109,"accession_number":"0001140361-25-007063","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin Therapeutics updates corporate presentation; no specific data in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing indicates updated corporate presentation posted on website March 5, 2025.","Presentation intended for use at conferences and investor meetings.","Exhibit content (slides) not included in provided text, limiting extractable news.","No new financial guidance, clinical milestones, or operational changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170108,"accession_number":"0001140361-25-004971","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Galectin reports 68.1% reduction in new varices with belapectin in U.S. patients from NAVIGATE trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Per-protocol U.S. patients (n=186): 68.1% reduction in new varices with belapectin 2 mg vs placebo (p=0.02).","New prevalence estimate: ~3 million U.S. adults with MASH cirrhosis and clinically significant portal hypertension.","Top-line composite endpoint missed statistical significance in ITT (N=355); completer analysis had 49.3% reduction (p=0.04 revised).","Full analysis ongoing; additional 36-month data expected by end of Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170107,"accession_number":"0001140361-25-002125","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galectin Therapeutics elects all 11 director nominees, ratifies auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected with votes for ranging from 18.2M to 19.0M; broker non-votes of 20.0M.","Ratification of Cherry Bekaert LLP as auditor: 38.7M for, 162.8K against, 408.9K abstain.","Annual meeting held January 23, 2025; directors elected for term until next annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170106,"accession_number":"0001140361-25-001687","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin Therapeutics furnishes annual meeting presentation transcript; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed a transcript of a presentation made after the January 23, 2025 Annual Meeting of Stockholders under Item 7.01.","The provided transcript excerpt contains only an opening thank-you and a forward-looking statement disclaimer; substantive content is absent from the filing.","No financial results, pipeline updates, or guidance changes are reported in the furnished exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170105,"accession_number":"0001140361-25-000879","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin Therapeutics updates corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated corporate presentation on January 13, 2025, available on company website.","Presentation intended for use at investor conferences and meetings.","No specific pipeline, financial, or clinical milestones disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187122,"accession_number":"0001140361-24-050005","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Galectin NAVIGATE trial: belapectin reduces varices by 48.9% in per-protocol but misses ITT primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In ITT (N=355), primary composite endpoint not statistically significant; varices incidence reduced 43.2% with 2mg/kg vs placebo.","In per-protocol (n=290), belapectin 2mg/kg showed 48.9% reduction in varices (p<0.05).","Safety profile favorable; adverse events comparable across cohorts, no drug-related SAEs.","Additional 36-month data from ~50 patients expected in Q1 2025.","Company will engage with potential partners to determine next steps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187121,"accession_number":"0001140361-24-046730","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin Therapeutics posts updated corporate presentation; exhibit truncated, specific content unknown","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed updated corporate presentation on Nov 14, 2024, for use at investor conferences and meetings.","Presentation available on company website; includes forward-looking statements.","Exhibit 99.1 appended but truncated in filing text; no new financial or pipeline details visible.","No specific guidance, trial results, or financing changes disclosed in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187120,"accession_number":"0001140361-24-046728","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics reports Q3 net loss of $11.2M; NAVIGATE trial top-line results expected Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.2M ($0.18/share) vs $14.0M ($0.24) in Q3 2023; R&D expense $7.6M, G&A $1.5M.","Cash $27.1M at Sept 30, 2024; $6M credit line from chairman; runway through May 2025.","NAVIGATE trial of belapectin in MASH cirrhosis top-line efficacy/safety results expected December 2024.","Three belapectin abstracts accepted for poster presentation at AASLD 2024 annual meeting.","Annual stockholder meeting set for January 23, 2025 due to NAVIGATE trial timing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203643,"accession_number":"0001140361-24-040509","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin posts updated corporate presentation; no specific material changes detailed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted to website on September 9, 2024.","Presentation intended for use at investor conferences and meetings.","Filing does not disclose specific financial or pipeline updates beyond the presentation format."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203642,"accession_number":"0001140361-24-036938","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics reports Q2 2024 net loss of $12.4M; NAVIGATE interim readout on track for Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NAVIGATE Phase 2b/3 trial of belapectin on track for interim top-line analysis in December 2024.","Cash and equivalents of $25.6M at June 30, 2024; $10M line of credit from chairman available.","Net loss for Q2 2024 was $12.4M ($0.20 per share) vs $9.2M ($0.15 per share) in Q2 2023.","R&D expenses rose to $9.8M from $7.4M, driven by NAVIGATE trial costs.","Cash runway expected to fund operations through approximately May 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203641,"accession_number":"0001140361-24-035212","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Galectin Therapeutics promotes Khurram Jamil to CMO, replacing Pol Boudes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jamil appointed Chief Medical Officer effective August 1, 2024, succeeding Dr. Pol Boudes.","Annual base salary of $500,000, 30% target bonus, 10,000 restricted shares, options for 100,000 shares.","Jamil joined Galectin in March 2024 as VP Clinical Development; previously at Mallinckrodt Pharmaceuticals.","Company reaffirms interim analysis of NAVIGATE Phase 2b/3 trial for belapectin in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220155,"accession_number":"0001140361-24-026106","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics Q1 net loss $0.19/share; cash $23.6M; NAVIGATE trial on track for Q4 2024 interim data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.5M ($0.19 per share) for Q1 2024, unchanged from Q1 2023.","Cash and equivalents $23.6M; additional $20M available from chairman's credit lines (two $10M facilities).","Fifth DSMB recommended continuation of NAVIGATE Phase 2b/3 trial of belapectin in MASH cirrhosis without modifications.","Interim top-line data from Phase 2b portion expected late Q4 2024.","Appointed Khurram Jamil, M.D. as Vice President of Clinical Development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239859,"accession_number":"0001140361-24-016454","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics reports FY2023 net loss of $44.8M; cash runway through March 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss applicable to common stockholders of $44.8M ($0.74/share) vs $38.9M ($0.65/share) in FY2022.","Cash and equivalents $25.7M at Dec 31; plus $20M available credit line and new $10M facility from chairman.","NAVIGATE Phase 2b/3 trial for belapectin in MASH cirrhosis fully enrolled (357 patients); interim analysis readout expected Q4 2024.","Appointed Benjamin S. Carson, Sr., M.D. to Board of Directors.","Fourth DSMB meeting authorized continuation of NAVIGATE trial without modifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257383,"accession_number":"0001140361-23-057155","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galectin Therapeutics announces 2023 annual meeting results; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected; highest vote total for Kary Eldred at 25,603,577 for.","Ratification of Cherry Bekaert LLP as auditor approved: 44,481,830 for, 252,254 against.","Amendment to 2019 Omnibus Equity Incentive Plan to add 3,000,000 shares approved: 23,901,293 for, 1,923,578 against, 18,910,166 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257382,"accession_number":"0001140361-23-056586","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin Therapeutics presents at annual meeting; transcript content not fully disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation after Annual Meeting of Stockholders on December 7, 2023.","Furnished transcript begins with a forward-looking statements disclaimer; no specific updates visible.","No financial results, product milestones, or material announcements are contained in the available exhibit portion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257381,"accession_number":"0001140361-23-052731","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics Q3 net loss $14M; cash $20.4M; Chairman exercises warrants for $10M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.0M ($0.24/sh) vs $8.6M ($0.14/sh) YoY; includes $3.6M non-cash deemed dividend from warrant modification.","Cash and equivalents $20.4M at Sept 30; additional $30M available under chairman's credit line.","Chairman Uihlein exercised 2.2M warrants at $4.49/sh for $10M gross proceeds; Dr. Benjamin Carson nominated to board.","R&D expenses $7.7M (up from $6.6M) on hiring and belapectin activities; G&A $1.4M (down from $1.5M).","Interim analysis for NAVIGATE belapectin trial on track for Q4 2023; company believes funded through Dec 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257380,"accession_number":"0001140361-23-052753","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K/A","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics Q3 net loss $14.0M ($0.24/share); chairman exercises warrants for $10M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.0M ($0.24 loss per share) vs $8.6M ($0.14) in Q3 2022; includes $3.6M non-cash deemed dividend from warrant modification.","Chairman Richard Uihlein exercised 2.24M warrants at $4.49/share, providing $10M cash; market price was $1.81.","Cash and equivalents $20.4M; additional $30M credit line from chairman; cash sufficient through at least Dec 2024.","Belapectin safety profile positive; interim analysis for NAVIGATE trial expected Q4 2024.","Dr. Benjamin Carson Sr. nominated to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274712,"accession_number":"0001140361-23-039412","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Q2 net loss $9.2M; NAVIGATE trial interim analysis expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.15 for Q2 2023 vs $0.16 in Q2 2022; R&D expenses $7.4M down from $8.1M.","Cash and equivalents $18.0M as of June 30, 2023; additional $30M available under chairman's credit line.","NAVIGATE trial (NASH cirrhosis) fully randomized with 357 patients; Phase 2b interim analysis expected Q4 2024.","Company evaluating Phase 2 trial of belapectin plus Keytruda in advanced head and neck cancers.","Belapectin safety profile remains encouraging; no approved therapy for NASH cirrhosis with portal hypertension."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292031,"accession_number":"0001140361-23-024500","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics Q1 net loss widens to $11.5M; NAVIGATE trial fully enrolled with 357 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.5M ($0.19/shr) vs $9.9M loss in Q1 2022, driven by higher R&D costs.","R&D expenses rose to $8.8M from $8.1M, primarily for the NAVIGATE trial.","Cash and equivalents $17.8M; additional $40M available under chairman's line of credit.","NAVIGATE Phase 2b/3 trial for NASH cirrhosis esophageal varices enrolled 357 patients; interim results expected Q4 2024.","Company evaluating potential Phase 2 trial of belapectin + Keytruda in advanced head and neck cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312771,"accession_number":"0001140361-23-014660","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics reports 2022 net loss of $38.9M; NAVIGATE trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.9M ($0.65/share) vs $30.7M ($0.52) in 2021.","R&D expenses $31.7M, up from $23.8M, driven by NAVIGATE trial costs.","Cash $18.6M; $50M credit line available; expects funding through Dec 2024.","NAVIGATE trial randomized 357 patients; DSMB positive; interim results Q4 2024.","Evaluating Phase 2 trial of belapectin + Keytruda for head and neck cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312770,"accession_number":"0001140361-23-009574","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Galectin completes NAVIGATE randomization with 357 patients; topline results Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Randomized 357 patients, exceeding initial target of ~315, in Phase 2b/3 belapectin study for NASH cirrhosis.","Last patient randomized end of February 2023; enrollment of new patients ended in late December 2022.","Study is first to evaluate primary prevention of esophageal varices in NASH cirrhosis with portal hypertension.","Topline interim results from Phase 2b portion expected in Q4 2024.","Trial enrolled patients across 14 countries on five continents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312769,"accession_number":"0001140361-23-000580","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Galectin completes enrollment in NAVIGATE Phase 2b/3 belapectin study for NASH cirrhosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["309 patients randomized to date; expects 325-340 total by early March 2023.","Phase 2b portion studies belapectin 2 mg/kg and 4 mg/kg vs. placebo (1:1:1).","Primary endpoint: primary prevention of esophageal varices in NASH cirrhosis with portal hypertension.","Interim analysis results expected in Q4 2024 after 18-month treatment period.","Study recruited patients across 14 countries and five continents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331296,"accession_number":"0001140361-22-044533","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galectin Therapeutics stockholders approve all proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; each received >16.6M votes for.","Ratified Cherry Bekaert LLP as independent auditor for FY2022 (36.3M for).","Approved issuance of up to 20M shares (max $60M principal) under Uihlein line of credit.","Non-binding advisory resolution on executive compensation passed (16.3M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331295,"accession_number":"0001140361-22-043963","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galectin Therapeutics makes presentation after Annual Meeting on December 1, 2022","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company held Annual Meeting of Stockholders virtually due to Covid-19 precautions.","Management and Board presented after the meeting; transcript attached as Exhibit 99.1.","Presentation included forward-looking statements with standard cautionary language.","Transcript filed with SEC on December 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331294,"accession_number":"0001140361-22-041172","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin reports Q3 2022 net loss $8.6M; NAVIGATE trial 88% enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.6M ($0.14/sh) for Q3 2022, unchanged from Q3 2021.","Cash $15.8M; plus $60M credit line; expects funding through Dec 2024.","NAVIGATE trial: 279 of 315 patients randomized, 74 in screening; target full enrollment around end-2022.","FDA allowed IND for belapectin + Keytruda in head and neck cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331293,"accession_number":"0001140361-22-036896","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA allows Galectin Therapeutics to proceed with Phase 2 trial of belapectin + Keytruda in head and neck cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued 'Study May Proceed' letter for Phase 2 trial of belapectin + pembrolizumab as first-line therapy for recurrent/metastatic PD-L1 positive head and neck squamous cell carcinoma.","This IND is the company's second; prior investigator-initiated study provided rationale for combination.","Company expects to complete enrollment in pivotal NAVIGATE trial in NASH cirrhosis around end of 2022.","Company plans to engage potential partners for oncology program; financing and trial start could occur next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331292,"accession_number":"0001140361-22-036339","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Galectin Therapeutics reports positive DSMB outcome for NAVIGATE study of belapectin in NASH cirrhosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second DSMB meeting recommends study continue as designed without modifications.","NAVIGATE is a seamless adaptive Phase 2b/3 trial of belapectin for primary prevention of esophageal varices in NASH cirrhosis.","Enrollment: 258 patients randomized; 74 in screening; full enrollment expected around year-end 2022.","DSMB confirms belapectin appears safe and well tolerated in fragile cirrhotic patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348835,"accession_number":"0001140361-22-029557","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics Q2 2022 net loss $9.7M; secures $60M credit line; trial enrollment 230 patients randomized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss applicable to common stockholders of $9.7M ($0.16/shr) vs $8.5M ($0.15/shr) in Q2 2021.","R&D expenses rose to $8.1M from $6.5M, driven by NAVIGATE trial costs.","Cash and equivalents $24.2M as of June 30, 2022; $60M line of credit from Richard Uihlein available.","NAVIGATE trial: 230 patients randomized, 70 in screening; enrollment expected to complete Q4 2022.","Planning to file IND with FDA for belapectin plus Keytruda in head and neck cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348834,"accession_number":"0001140361-22-026910","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2022-07-26T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","9.01"],"status":"ready","headline":"Galectin Therapeutics secures $60M credit line from chairman; CEO extends stock compensation","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$60M unsecured line of credit from Chairman Richard Uihlein through July 31, 2024; principal & interest due Jan 31, 2026.","Interest at AFR (2.84%) + 2%; conversion price at closing price but not below $3.00 per share.","Initial warrant for 500k shares at $5.00; up to 1.2M additional warrants at 150% of draw closing price (floor $3, cap $10).","CEO Joel Lewis extends 80% stock compensation through Dec 2023; employment term extended to Dec 2024.","Proceeds expected to fund operations through 2024; NAVIGATE phase 2b results expected mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365634,"accession_number":"0001140361-22-019249","cik":1133416,"company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galectin Therapeutics Q1 net loss $9.9M ($0.17/shr); cash runway through May 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.9M for Q1 2022 vs $6.3M in Q1 2021; R&D spend rose to $8.1M (up from $4.9M) on NAVIGATE trial costs.","Cash and equivalents $31.6M; company expects to fund operations through at least May 16, 2023.","Expects to require additional $40-45M to reach planned interim analysis of NAVIGATE trial in mid-2024.","Phase 2b/3 NAVIGATE trial enrollment for NASH cirrhosis on track to finish Phase 2b portion around Q3 2022.","Company preparing IND to study belapectin in combination with Keytruda for recurrent head and neck cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174520776.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-16T23:59:59+00:00|365634"}